- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06542874
Een onderzoeksstudie waarin wordt vergeleken hoe goed verschillende doses van het medicijn NNC0487-0111 de bloedsuikerspiegel verlagen bij mensen met diabetes type 2
Veiligheid en werkzaamheid van eenmaal per week subcutaan en eenmaal daags oraal NNC0487-0111 bij deelnemers met diabetes type 2 - een dosisbepalend onderzoek
The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type 2 diabetes. NNC0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Participants will either get NNC0487-0111, which is given as tablets or as injections, or placebo. Which treatment the participant get is decided by chance.The study will last for about 43 weeks.
Studie Overzicht
Toestand
Conditie
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
-
Kyustendil, Bulgarije, 2500
- Individual Practice For Specialized Outpatient Medical Care Doctor Miglena Rizova Ltd.
-
Kyustendil, Bulgarije, 2500
- IPSOMC Dr. Miglena Rizova Ltd.
-
Plovdiv, Bulgarije, 4002
- DCC Sveti Georgi EOOD
-
Plovdiv, Bulgarije, 4001
- UMHAT "Kaspela", Depart. Endocrinology and Metab. Diseases
-
Plovdiv, Bulgarije, 4002
- Diagnostic-Consultative Centre "Sveti Georgi" Eood
-
Plovdiv, Bulgarije, 4001
- UMHAT Kaspela EOOD, Endocrinology and Metabolic Diseases Clinic
-
Sofia, Bulgarije, 1431
- USHATE "Akad. Ivan Penchev" Second Clinic of Endocrinology
-
Sofia, Bulgarije, 1431
- UMHAT "Aleksandrovska"
-
Sofia, Bulgarije, 1000
- Medical centre Regina Life Clinic EOOD
-
Sofia, Bulgarije, 1431
- USHATE Akad. Ivan Penchev EAD, Second Clinic of Endocrinology
-
Sofia, Bulgarije, 1431
- UMHAT Aleksandrovska EAD, Densitometry and Bone Metabolic Diseases
-
Varna, Bulgarije, 9020
- AIPSMC Dr. Artin Magardichyan EOOD
-
-
-
-
-
Elsterwerda, Duitsland, 04910
- Zentrum für klinische Studien Südbrandenburg GmbH
-
Elsterwerda, Duitsland, 04910
- Zentrum fuer klinische Studien Suedbrandenburg GmbH
-
Essen, Duitsland, 45136
- InnoDiab Forschung GmbH
-
Hamburg, Duitsland, 22607
- Wendisch/Dahl Hamburg
-
Hamburg, Duitsland, 22607
- Wendisch - Dahl Hamburg - DZHW
-
Münster, Duitsland, 48145
- Institut für Diabetesforschung GmbH Münster - Dr. med. Rose
-
Oldenburg in Holstein, Duitsland, 23758
- RED-Institut für medizinische Forschung und Fortbildung GmbH
-
-
-
-
-
Athens, Griekenland, 115 25
- Iatriko Psychicou Private Clinic
-
Athens, Griekenland, 12462
- U.G.H of Athens "Attikon"
-
Goudi/Athens, Griekenland, 11527
- "Laiko" General Hospital of Athens
-
Thessaloniki, Griekenland, GR-54643
- EUROMEDICA Gen Clinic The/ki, Endocrin,Metabolism,Diabetes
-
Thessaloniki, Griekenland, GR-57001
- "Thermi" Private Hosital
-
Thessaloniki, Griekenland, 564 29
- 424 Military General Training Hospital
-
Thessaloniki, Griekenland, 57001
- "Thermi" Private Hosital
-
Thessaloniki, Griekenland, 54645
- EUROMEDICA Gen Clinic The/ki, Endocrin,Metabolism,Diabetes
-
Thessaloniki, Griekenland, 564 29
- 424 Military General Training Hospital - 2nd Department of Internal Medicine
-
-
-
-
-
Budapest, Hongarije, 1106
- Bajcsy-Zsilinszky Kórház
-
Budapest, Hongarije, 1134
- MH Egészségügyi Központ
-
Debrecen, Hongarije, 4031
- Debreceni Egyetem
-
Debrecen, Hongarije, H-4031
- Debreceni Egyetem
-
Debrecen, Hongarije, H-4032
- Debreceni Egyetem
-
Gyula, Hongarije, 5700
- Békés Megyei Központi Kórház
-
Kaposvár, Hongarije, 7400
- Somogy Vármegyei Kaposi Mór Oktató Kórház
-
Kaposvár, Hongarije, H-7400
- Somogy Vármegyei Kaposi Mór Oktató Kórház
-
-
Hajdú-Bihar
-
Debrecen, Hajdú-Bihar, Hongarije, 4032
- Debreceni Egyetem
-
-
-
-
-
Aichi, Japan, 468-0009
- TOSAKI Clinic for Diabetes and Endocrinology_Diabetes and Endocrinology
-
Chiba, Japan, 261-0004
- Tokuyama clinic_Diabetic internal medicine
-
Chiba, Japan, 261-0004
- Tokuyama clinic
-
Chiba-shi, Chiba, Japan, 260-0804
- Akaicho Clinic
-
Ibaraki, Japan, 311-0113
- Naka Kinen Clinic
-
Ibaraki, Japan, 311-0113
- Naka Kinen Clinic_Internal medicine
-
Tokyo, Japan, 103-0027
- Tokyo-Eki Center-building Clinic
-
Tokyo, Japan, 104-0031
- Fukuwa Clinic
-
Tokyo, Japan, 103-0027
- Tokyo-Eki Center-building Clinic_Internal Medicine
-
Tokyo, Japan, 104-0031
- Fukuwa Clinic_Internal Medicine
-
-
Miyazaki
-
Miyazaki, Miyazaki, Japan, 880-0034
- Heiwadai Hospital_Internal Medicine
-
Miyazaki, Miyazaki, Japan, 880-0034
- Heiwadai Hospital
-
-
-
-
-
Karlovac, Kroatië, 47000
- Opca bolnica Karlovac
-
Krapinske Toplice, Kroatië, 49217
- Specijalna bolnica Krapinske Toplice - Endokrinologija
-
Krapinske Toplice, Kroatië, 49217
- Specijalna Bolnica za medicinsku rehabilitaciju Krapinske Toplice_Endocrinology
-
Osijek, Kroatië, 31 000
- Klinicki bolnicki centar Osijek_Endocrinology
-
Osijek, Kroatië, 31 000
- Klinicki bolnicki centar Osijek
-
Varaždin, Kroatië, 42 000
- Opca bolnica Varazdin_Endocrinology
-
Varaždin, Kroatië, 42 000
- Opca bolnica Varazdin
-
-
City of Zagreb
-
Zagreb, City of Zagreb, Kroatië, 10000
- Poliklinika Solmed
-
-
Primorje-Gorski Kotar County
-
Rijeka, Primorje-Gorski Kotar County, Kroatië, 51 000
- KBC Rijeka, Endokrinologija
-
Rijeka, Primorje-Gorski Kotar County, Kroatië, 51 000
- Clinical Hospital Centre Rijeka_Endocrinology
-
-
-
-
-
Bialystok, Polen, 15-375
- Specderm Poznańska Spółka Jawna
-
Lublin, Polen, 20-718
- EKAMED sp. z o.o.
-
Ruda Śląska, Polen, 41-709
- Niepubliczny Zaklad Opieki Zdrowotnej Przychodnia Specjalistyczna A Wittek H Rudzki Sp. j.
-
Warsaw, Polen, 02-507
- PANSTWOWY INSTYTUT MEDYCZNY MSWiA
-
-
Gornoslaskie
-
Ruda Śląska, Gornoslaskie, Polen, 41-709
- Niepubliczny Zaklad Opieki Zdrowotnej Przychodnia Specjalistyczna A Wittek H Rudzki Sp. j.
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Polen, 31-261
- Med. Cent. Diabet. Endo. Metabol. DIAB-ENDO-MET
-
Oświęcim, Lesser Poland Voivodeship, Polen, 32-600
- Formed 2 Sp. z o.o.
-
-
Lower Silesian Voivodeship
-
Legnica, Lower Silesian Voivodeship, Polen, 59-220
- Beata Mikłaszewicz & Dariusz Dąbrowski "CARDIAMED" s.j.
-
Legnica, Lower Silesian Voivodeship, Polen, 59-220
- Beata Miklaszewicz & Dariusz Dabrowski "CARDIAMED" s.j.
-
-
Lublin Voivodeship
-
Lublin, Lublin Voivodeship, Polen, 20-718
- EKAMED sp. z o.o.
-
-
Masovian Voivodeship
-
Siedlce, Masovian Voivodeship, Polen, 08-110
- ETG Siedlce
-
-
Podlaskie Voivodeship
-
Bialystok, Podlaskie Voivodeship, Polen, 15-879
- NZOZ Vita-Diabetica Malgorzata Buraczyk
-
Bialystok, Podlaskie Voivodeship, Polen, 15-375
- Specderm Poznanska Sp. j.
-
-
Łódź Voivodeship
-
Lodz, Łódź Voivodeship, Polen, 90-302
- Santa Sp. z o.o, Santa Familia Centrum Badan, Profilaktyki i Leczenia
-
-
-
-
-
Brasov, Roemenië, 500101
- Mariodiab Clinic SRL
-
Timișoara, Roemenië, 300723
- Spitalul Clinic Judetean De Urgenta Pius Brinzeu Timisoara
-
Timișoara, Roemenië, 300288
- Cabinet Medical Dr Geru SRL
-
-
Bihor County
-
Oradea, Bihor County, Roemenië, 410025
- SC Grand Med SRL
-
Oradea, Bihor County, Roemenië, 410159
- Grandmed SRL
-
-
Bucharest
-
Bucharest, Bucharest, Roemenië, 020475
- Institutul National De Diabet Nutritie Si Boli Metabolice Prof.Dr.N.Paulescu Bucuresti- Ion Movila
-
-
Bucurestii
-
Bucharest, Bucurestii, Roemenië, 020475
- Institutul National De Diabet Nutritie Si Boli Metabolice Prof.Dr.N.Paulescu Bucuresti- Ion Movila
-
-
Cluj
-
Cluj-Napoca, Cluj, Roemenië, 400006
- Spitalul Clinic Judetean Urgenta Cluj-Napoca
-
-
Mureș County
-
Târgu Mureş, Mureș County, Roemenië, 540142
- Sc Mediab Srl
-
-
Prahova
-
Ploieşti, Prahova, Roemenië, 100018
- Novus Medical Clinica SRL
-
-
-
-
-
Poprad, Slowakije, 05801
- DENTAVIA s.r.o.
-
Prešov, Slowakije, 080 01
- DIABETOL, s.r.o.
-
Rimavská Sobota, Slowakije, 979 01
- OLIVER - MED s.r.o.
-
Žilina, Slowakije, 010 01
- MEDIVASA, s.r.o., Diabetologicka ambulancia
-
-
Slovak Republic
-
Šahy, Slovak Republic, Slowakije, 93601
- Peter Farkas MD, s.r.o.
-
-
-
-
-
A Coruña, Spanje, 15006
- Complejo Hospitalario Universitario A Coruña
-
Barcelona, Spanje, 08036
- Hospital Clinic i Provincial
-
Castilleja de la Cuesta, Spanje, 41950
- Hospital Vithas Sevilla
-
Madrid, Spanje, 28007
- Hospital Gregorio Marañón
-
Pontevedra, Spanje
- Complejo Hospitalario de Pontevedra - Hospital de Montecelo
-
Santander, Spanje, 39008
- Hospital Universitario Marqués de Valdecilla
-
Seville, Spanje, 41003
- Clínica Nuevas Tecnologías en Diabetes y Endocrinología
-
Seville, Spanje, 41010
- Hospital Infanta Luisa
-
Seville, Spanje, 41950
- Hospital Nisa Sevilla Aljarafe
-
Seville, Spanje, 41010
- H. Infanta Luisa_Endocrino y Obesidad
-
-
-
-
Alabama
-
Birmingham, Alabama, Verenigde Staten, 35294
- Uni of Alabama at Birmingham
-
-
California
-
Los Angeles, California, Verenigde Staten, 90057
- Velocity Clin Research LA
-
Santa Ana, California, Verenigde Staten, 92701
- Southern Cal Clinical Research
-
-
Connecticut
-
Waterbury, Connecticut, Verenigde Staten, 06708
- Chase Medical Research LLC
-
-
Florida
-
Fleming Island, Florida, Verenigde Staten, 32003
- Fleming Island Ctr for Clin Res
-
Hollywood, Florida, Verenigde Staten, 33024
- Encore Medical Research LLC
-
Miramar, Florida, Verenigde Staten, 33027
- South Broward Research LLC
-
Orlando, Florida, Verenigde Staten, 32825
- Florida Inst For Clin Res
-
Orlando, Florida, Verenigde Staten, 32825
- Florida Institute for Clinical research
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60607
- Cedar-Crosse Research Center
-
-
Kansas
-
Topeka, Kansas, Verenigde Staten, 66606
- Cotton O'Neil Clinical Research Center
-
-
Kentucky
-
Paducah, Kentucky, Verenigde Staten, 42001
- Advanced Internal Medicine, PLLC
-
-
Maryland
-
Hyattsville, Maryland, Verenigde Staten, 20782
- Medstar Research Institute_Hyattsville
-
Oxon Hill, Maryland, Verenigde Staten, 20745
- MD Medical Research
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02115
- Brigham & Women's Hospital
-
Methuen, Massachusetts, Verenigde Staten, 01844
- ActivMed Practice & Research LLC
-
-
Michigan
-
Troy, Michigan, Verenigde Staten, 48098
- Arcturus Healthcare, PLC
-
Troy, Michigan, Verenigde Staten, 48098
- Arcturus HC PLC Troy Med Res
-
-
Missouri
-
Chesterfield, Missouri, Verenigde Staten, 63005
- Clinical Research Professionals
-
City of Saint Peters, Missouri, Verenigde Staten, 63303
- StudyMetrix Research LLC
-
-
New York
-
Albany, New York, Verenigde Staten, 12203
- AMC Community Endocrinology
-
-
North Carolina
-
Morehead City, North Carolina, Verenigde Staten, 28557
- Centricity Rsrch MHCity Multi
-
Statesville, North Carolina, Verenigde Staten, 28625
- Piedmont Healthcare/Research
-
-
North Dakota
-
Fargo, North Dakota, Verenigde Staten, 58104
- Lillestol Research LLC
-
Fargo, North Dakota, Verenigde Staten, 58104
- Plains Clinical Research Center, LLC_Fargo
-
-
Oklahoma
-
Norman, Oklahoma, Verenigde Staten, 73069
- Alliance for Multispec Res
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19107-6810
- Jefferson Endocrinology Assocs
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15236
- Preferred Primary Care Physicians_Pittsburgh
-
-
South Dakota
-
Rapid City, South Dakota, Verenigde Staten, 57702
- Health Concepts
-
-
Tennessee
-
Kingsport, Tennessee, Verenigde Staten, 37660
- Holston Medical Group
-
Nashville, Tennessee, Verenigde Staten, 37203
- Clinical Research Associates
-
Nashville, Tennessee, Verenigde Staten, 37203
- MidState Endocrine Associates
-
-
Texas
-
Dallas, Texas, Verenigde Staten, 75230
- Velocity Clinical Res-Dallas
-
Houston, Texas, Verenigde Staten, 77024
- Victorium Clinical Research
-
Houston, Texas, Verenigde Staten, 77079
- PlanIt Research, PLLC
-
Houston, Texas, Verenigde Staten, 77061
- Synergy Groups Medical
-
Lampasas, Texas, Verenigde Staten, 76550
- Radiance Clinical Research
-
McKinney, Texas, Verenigde Staten, 75069
- Tekton Research
-
Waco, Texas, Verenigde Staten, 76708
- Hillcrest Family Health Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Male or female, aged 18-75 years (both inclusive) at the time of signing the informed consent.
- Diagnosed with type 2 diabetes mellitus greater or equal to 180 days before screening.
- Stable daily dose(s) greater or equal to 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without SGLT2 inhibitor.
- HbA1c of 7.0-10.0 procent (53-86 mmol/mol) (both inclusive) as assessed by central laboratory at screening.
- Body mass index between greater or equal to 23.0 and below 50.0 kg/m^2.
- Able and willing to adhere to the protocol including wearing a continuous glucose monitoring (CGM) device provided for the study, as judged by the investigator.
Exclusion Criteria:
- Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
- Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Placebo-vergelijker: Placebo subcutaneous
Placebo for subcutaneous treatment |
NNC0487-0111 placebo administered subcutanously (under the skin) |
|
Experimenteel: NNC0487-0111 subcutaneous dose 1
NNC0487-0111 subcutaneous dose 1 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
Experimenteel: NNC0487-0111 subcutaneous dose 2
NNC0487-0111 subcutaneous dose 2 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
Experimenteel: NNC0487-0111 subcutaneous dose 3
NNC0487-0111 subcutaneous dose 3 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
Experimenteel: NNC0487-0111 subcutaneous dose 4
NNC0487-0111 subcutaneous dose 4 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
Experimenteel: NNC0487-0111 subcutaneous dose 5
NNC0487-0111 subcutaneous dose 5 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
Experimenteel: NNC0487-0111 subcutaneous dose 6
NNC0487-0111 subcutaneous dose 6 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
Placebo-vergelijker: Placebo oral
Placebo for oral treatment |
NNC0487-0111 placebo administered orally (in the mouth) |
|
Experimenteel: NNC0487-0111 oral dose 1
NNC0487-0111 oral dose 1 treatment |
NNC0487-0111 administered orally (in the mouth) |
|
Experimenteel: NNC0487-0111 oral dose 2
NNC0487-0111 oral dose 2 treatment |
NNC0487-0111 administered orally (in the mouth) |
|
Experimenteel: NNC0487-0111 oral dose 3
NNC0487-0111 oral dose 3 treatment |
NNC0487-0111 administered orally (in the mouth) |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change in HbA1c
Tijdsspanne: From baseline (week 0) to end of treatment (week 36)
|
percent point |
From baseline (week 0) to end of treatment (week 36)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Relative change in body weight
Tijdsspanne: From baseline (week 0) to end of treatment (week 36)
|
percent |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in body weight
Tijdsspanne: From baseline (week 0) to end of treatment (week 36)
|
kg |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in fasting plasma glucose (FPG)
Tijdsspanne: From baseline (week 0) to end of treatment (week 36)
|
mmol/L |
From baseline (week 0) to end of treatment (week 36)
|
|
CGM: Change in time in range (TIR) 3.9-10.0 mmol/L (70-180 mg/dL)
Tijdsspanne: From baseline (week 0) to end of treatment (week 36)
|
percent points |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in body mass index (BMI)
Tijdsspanne: From baseline (week 0) to end of treatment (week 36)
|
kg/m^2 |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in waist circumference
Tijdsspanne: From baseline (week 0) to end of treatment (week 36)
|
cm |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in systolic blood pressure (SBP)
Tijdsspanne: From baseline (week 0) to end of treatment (week 36)
|
mmHg |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in average 24-hour systolic blood pressure (SBP)
Tijdsspanne: From baseline (week 0) to end of treatment (week 36)
|
mmHg |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in high sensitivity C-Reactive Protein (hsCRP)
Tijdsspanne: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in total cholesterol
Tijdsspanne: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in high-density lipoprotein (HDL) cholesterol
Tijdsspanne: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in low-density lipoprotein (LDL) cholesterol
Tijdsspanne: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in triglycerides
Tijdsspanne: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Number of adverse events
Tijdsspanne: From baseline (week 0) to end of study (week 40)
|
Count of events |
From baseline (week 0) to end of study (week 40)
|
|
Change in Urinary Albumin/Creatinine Ratio (UACR)
Tijdsspanne: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Participant without macroalbuminuria (UACR < 300 mg/g) at baseline (week 0) developing (yes/no) new onset of macroalbuminuria (UACR ≥ 300 mg/g)
Tijdsspanne: At end of treatment (week 36)
|
Count of participant |
At end of treatment (week 36)
|
|
Change in eGFR creatinine- and cystatin C based CKD-EPI
Tijdsspanne: From baseline (week 0) to end of treatment (week 36)
|
mL/min/1.73 m^2 |
From baseline (week 0) to end of treatment (week 36)
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Publicaties en nuttige links
Algemene publicaties
- Mora P, Aroda VR, Asong M, Bluher M, Heftdal LD, Carlander AF, Vilsen LN, Rosenstock J. Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. Lancet. 2026 Jul 30:S0140-6736(26)01248-1. doi: 10.1016/S0140-6736(26)01248-1. Online ahead of print.
- Mora P, Aroda VR, Asong M, Bluher M, Carlander AF, Kaltoft M, Vilsen LN, Rosenstock J. Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. Lancet. 2026 Jul 30:S0140-6736(26)01247-X. doi: 10.1016/S0140-6736(26)01247-X. Online ahead of print.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- NN9490-7678
- U1111-1296-9708 (Andere identificatie: World Health Organization (WHO))
- 2023-509412-28 (Andere identificatie: European Medical Agency (EMA))
- 2023 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .